Insulet (PODD) P/B ratio
Insulet (PODD) trades at 6.9× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 13.5×. That is 15.3% lower than the 15.9× of fiscal 2024. Figures as of 18 Nov 2026, 07:19 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio today
- 6.9×
- P/B ratio, fiscal 2025
- 13.5×
- Change on fiscal 2024
- −15.3%
- Highest on record
- 140.5×fiscal 2019
- Lowest on record
- 13.5×fiscal 2025
- Fiscal years on record
- 102016–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Insulet P/B ratio, in more detail
Today's figure is 48.9% below the fiscal 2025 year-end.
Across the 10 fiscal year-ends on record (2016–2025), the highest was 140.5× in fiscal 2019 and the lowest 13.5× in fiscal 2025. Today's P/B ratio is at or below every one of the 10 fiscal year-ends on record; their median is 26.6×.
P/B ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Insulet P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| Today | 6.9× | — | $145.34 | — | |
| 2025 | 13.5× | 15.3% down | $284.24 | $21.08 | |
| 2024 | 15.9× | 27.0% down | $261.07 | $16.40 | |
| 2023 | 21.8× | 49.5% down | $216.98 | $9.95 | |
| 2022 | 43.2× | 31.7% up | $294.39 | $6.81 | |
| 2021 | 32.8× | 17.4% up | $266.07 | $8.11 | |
| 2020 | 27.9× | 80.1% down | $255.63 | $9.15 | |
| 2019 | 140.5× | 516.0% up | $171.20 | $1.22 | |
| 2018 | 22.8× | 9.6% down | $79.32 | $3.48 | |
| 2017 | 25.3× | 26.1% down | $69.00 | $2.73 | |
| 2016 | 34.2× | — | $37.68 | $1.10 | |
| 2015 | — | — | $37.81 | — | |
| 2014 | — | — | $46.06 | — | |
| 2013 | — | — | $37.10 | — | |
| 2012 | — | — | $21.22 | — | |
| 2011 | — | — | $18.83 | — | |
| 2010 | — | — | $15.50 | — | |
| 2009 | — | — | $14.28 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
P/B ratio at health care companies of similar size
| Company | P/B ratio |
|---|---|
| Vaxcyte PCVX | 3.5× |
| Bio-Rad Laboratories BIO | 1.3× |
| Molina Healthcare MOH | 2.8× |
| Spyre Therapeutics SYRE | 12.5× |
| Qiagen QGEN | 2.7× |
| Insulet PODD | 6.7× |
Today's market value divided by shareholders' equity at the latest fiscal year-end. A company whose statements are in another currency than its shares is left out.
Insulet, figure by figure
- Insulet market cap
- Insulet revenue
- Insulet earnings
- Insulet earnings per share (EPS)
- Insulet P/E ratio
- Insulet P/S ratio
- Insulet free cash flow
- Insulet operating margin
- Insulet dividend
- Insulet shares outstanding
- Insulet total debt
- Insulet cash on hand
- Insulet total assets
- Insulet return on equity (ROE)
- Insulet return on invested capital (ROIC)
Insulet (PODD) overview: price, valuation and scorecardAll health care companies by market value
Insulet P/B ratio: questions and answers
What is Insulet's P/B ratio?
Insulet (PODD) trades at 6.9× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 13.5×. That is 15.3% lower than the 15.9× of fiscal 2024.
Is Insulet's P/B ratio high or low compared with its own history?
Today's P/B ratio is at or below every one of the 10 fiscal year-ends on record; their median is 26.6×.
What are the highest and lowest P/B ratio figures on record for Insulet?
Across the 10 fiscal year-ends on record (2016–2025), the highest was 140.5× in fiscal 2019 and the lowest 13.5× in fiscal 2025.
How is Insulet's P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Insulet (PODD) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/PODD/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.